SCHEMBL19717823

SCHEMBL19717823

CN(CCN1CCN(C(=O)O)CC1)C(=O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 5/20 0.46
▸ SIGMAR1 Q99720 6/20 0.45
▸ TEAD3 Q99594 1/20 0.44
▸ CCR5 P51681 1/20 0.42
▸ CHRM5 P08912 2/20 0.42
▸ CHRM2 P08172 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ BCHE P06276 1/20 0.42
▸ ACHE P22303 1/20 0.42
▸ TMEM97 Q5BJF2 3/20 0.42
▸ HTR1A P08908 1/20 0.42
▸ ADRA2A P08913 1/20 0.42
▸ ADRA2B P18089 1/20 0.42
▸ DRD1 P21728 1/20 0.42
▸ DRD4 P21917 1/20 0.42
▸ DRD5 P21918 1/20 0.42
▸ ADRA1D P25100 1/20 0.42
▸ HTR1D P28221 1/20 0.42
▸ HTR1B P28222 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4283767 0.87 HRH3 (0.56) HRH3SIGMAR1
SCHEMBL19717423 0.86 MEN1 (0.46) SIGMAR1CHRM2CHRM1CHRM3ACHE
SCHEMBL16197464 0.80 ATM (0.41) HRH3SIGMAR1TEAD3CCR5TMEM97
SCHEMBL16197465 0.80 ALDH1A1 (0.42) HRH3SIGMAR1TEAD3CCR5CHRM1
SCHEMBL16197753 0.80 ATM (0.41) HRH3SIGMAR1TEAD3CCR5TMEM97
SCHEMBL21997547 0.80 ACKR3 (0.48) SIGMAR1TEAD3CHRM2CHRM1CHRM3
SCHEMBL7367495 0.79 ALDH1A1 (0.58) SIGMAR1KMT2A
SCHEMBL21997329 0.78 SIGMAR1 (0.50) SIGMAR1CHRM5CHRM2CHRM1CHRM3
SCHEMBL27482008 0.78 ALDH1A1 (0.51) HRH3SIGMAR1CCR5CHRM5CHRM2
SCHEMBL5151581 0.78 ESR2 (0.40) HRH3SIGMAR1CCR5CHRM5CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3468953-B1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE IP DEV LTD (GB) 2024-05-22 — — EP disclosed
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-13 — — US disclosed
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-06-27 — — US disclosed
EP-3468953-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GlaxoSmithKline Intellectual Property Development Limited (GB) 2019-04-17 — — EP disclosed
WO-2017216727-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 — — WO disclosed
WO-2017216726-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 DNMT1, DNMT3A, DNMT3B HRH3 3505/4885SIGMAR1 551/4885TEAD3 554/4885
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 DNMT1, DNMT3A, DNMT3B HRH3 3505/4885SIGMAR1 551/4885TEAD3 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback